Nexgel (NXGLW) Research & Development (2021 - 2026)

Nexgel (NXGLW) has reported Research & Development for 6 consecutive years, with $20000.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Research & Development changed N/A year-over-year to $20000.0; the trailing twelve-month figure through Jun 2026 stood at $21000.0 (up 2000.0% YoY), and the FY2025 full-year result was $2000.0, down 97.44% from the prior year.
• Research & Development rose to $20000.0 in Q2 2026 per NXGLW's latest filing, from -$6000.0 in the prior quarter.
• Across five years, Research & Development topped out at $193000.0 in Q3 2022 and bottomed at -$6000.0 in Q4 2025.
• Historically, Research & Development has averaged $40714.3 across 5 years, with a median of $22000.0 in 2022.
• The sharpest annual moves came in 2022 and 2023: Research & Development surged 1010.0% in 2022, then slumped 96.89% in 2023.
• Over 5 years, Research & Development stood at $39000.0 in 2022, then plunged by 66.67% to $13000.0 in 2023, then soared by 484.62% to $76000.0 in 2024, then tumbled by 107.89% to -$6000.0 in 2025, then surged by 433.33% to $20000.0 in 2026.
• According to Business Quant data, Research & Development over the past three periods registered $20000.0, -$6000.0, and $7000.0 for Q2 2026, Q4 2025, and Q3 2025 respectively.